scholarly journals Analysis of the optimal body fluid level using a body composition analyzer as well as CRIT-LINE in patients undergoing hemodialysis.

1999 ◽  
Vol 32 (3) ◽  
pp. 199-203 ◽  
Author(s):  
Shunichi Maejima ◽  
Tadahiko Iwamoto ◽  
Shuzo Kobayashi
Keyword(s):  
Body Composition ◽  
Body Fluid ◽  
Fluid Level ◽  
Composition Analyzer

The Study of Skeletal Muscle Weight Change on Female Elder Adults

2013 ◽  
Vol 680 ◽  
pp. 602-605
Author(s):  
Chang Tsang Yeh ◽  
Shu Cheng Lin ◽  
Hung Tai Lin ◽  
Hsuan Chun Tsai ◽  
Ho Cheng Cheng
Keyword(s):  
Skeletal Muscle ◽  
Body Composition ◽  
Older Adult ◽  
Weight Change ◽  
Age Groups ◽  
Composition Analysis ◽  
Muscle Weight ◽  
Significance Level ◽  
Composition Analyzer ◽  
Post Menopausal

There are several problems after post-menopausal and higher age in the female. It may affect their physiological results, especially in the changes of their body composition. Older adults change their skeletal muscle weight when they are aging. But what differences their skeletal muscle weight change is still unknown. There is little previous research. Therefore, the purpose of this study was to investigate skeletal muscle weight change on female older adult. Methods: 48 women aged 41-80 years old were randomly selected and divided into four different age groups: 41-50 y (14 persons, abbreviated as number), 51-60 y (12), 61-70 y (12) and 71-80 y (10). All subjects’ body compositions were measured. Body composition analysis was conducted using the In Body 220 body composition analyzer. Data analysis was conducted using the SPSS statistical software for Windows 15.0. Independent one-way ANOVA was used as the statistical method at a significance level (α) of .05, followed by the Scheffé’s method to account for multiple comparisons. Results: Statistical analyses show that means of 4 skeletal muscle weight groups was 22.27±2.12(kg), 21.41±2.12(kg), 21.16±2.25(kg), 16.64±1.98(kg), there is significant differences in between 41-50y, 51-60y, 61-70y and 70-80 y group (Scheffé：41-70 y＞70-80 y). Conclusions: This research conclusion is that the skeletal muscle weight were similar from 41 years old to 70 years old in female older adult. But after 71 years old the skeletal muscle weight aging quickly.

scholarly journals Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study

2019 ◽  
Author(s):  
Haruka Tamura ◽  
Yoshinobu Kondo ◽  
Kohei Ito ◽  
Masanori Hasebe ◽  
Shinobu Satoh ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Composition ◽  
Endothelial Function ◽  
Cardiovascular Events ◽  
Body Fluid ◽  
Microvascular Complications ◽  
Fluid Volume ◽  
Controlled Study ◽  
Body Fluid Volume

Abstract Background : Patients with type 2 diabetes at high risk of cardiovascular events and receiving empagliflozin have a lower rate of primary composite cardiovascular outcomes and death from any cause. Alternatively, treatment with sulfonylurea reduces microvascular complications in diabetes but appears to increase cardiovascular hospitalization or mortality in combination with metformin. In the present study, we therefore assessed the effects of empagliflozin and glimepiride, a sulfonylurea, on endothelial function using flow–mediated dilation (FMD) to estimate arteriosclerosis and cardiovascular events in patients with type 2 diabetes. Methods : In this prospective, randomized, parallel-group comparison, 58 patients with type 2 diabetes were administered metformin and glargine before bedtime for 12 weeks, followed by the random addition of 10 mg empagliflozin or 0.5 mg glimepiride for 12 weeks. The primary outcome was FMD changes (ΔFMDs), which were measured prior to and following 12 weeks of additional treatment. Secondary outcomes comprised changes in metabolic markers and body composition. Results : Analysis of the empagliflozin group ( n = 30) and glimepiride group ( n = 28) showed no significant differences in DFMDs (empagliflozin, −0.19 ± 2.34%; glimepiride, −0.37 ± 2.77%; P ＝ 0.79); likewise, HbA1c changes were similar between the groups. Body weight changes significantly differed (empagliflozin, –0.59 ± 2.5 kg; glimepiride, 1.2 ± 3.0 kg; P = 0.02). However, analysis of body composition revealed that body fluid volume significantly decreased only after empagliflozin treatment (baseline, 35.8 ± 6.8 L; after 12 weeks, –0.33 ± 0.72 L; P = 0.03). Conclusions : Empagliflozin did not improve endothelial function compared with glimepiride in patients with type 2 diabetes, but decreased body fluid volume. This suggested that the coronary protective effect of empagliflozin is not derived by protecting endothelial function but rather from reducing heart failure.

scholarly journals Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study

2019 ◽  
Author(s):  
Haruka Tamura ◽  
Yoshinobu Kondo ◽  
Kohei Ito ◽  
Masanori Hasebe ◽  
Shinobu Satoh ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Composition ◽  
Endothelial Function ◽  
Body Fluid ◽  
Microvascular Complications ◽  
Fluid Volume ◽  
The Body ◽  
Controlled Study ◽  
Body Fluid Volume

Abstract Background: Among patients with type 2 diabetes and established cardiovascular disease, those receiving empagliflozin have a lower rate of primary composite cardiovascular outcomes and death from any cause. Alternatively, treatment with sulfonylurea reduces microvascular complications in diabetes but appears to increase cardiovascular hospitalization or mortality in combination with metformin. Therefore, in the present study, we assessed the effects of empagliflozin and glimepiride, a sulfonylurea, on endothelial function using flow–mediated dilation (FMD) to estimate arteriosclerosis and cardiovascular events in patients with type 2 diabetes. Methods: In this prospective, open-label, randomized, parallel-group comparison, 58 patients with type 2 diabetes were administered metformin and glargine before bedtime for 12 weeks, followed by the random addition of 10 mg empagliflozin or 0.5 mg glimepiride for 12 weeks. The primary outcome was the change in the FMD measurement (DFMDs), which was measured prior to and following 12 weeks of additional treatment. Secondary outcomes comprised changes in metabolic markers and body composition. Results: Analysis of the empagliflozin group (n = 30) and glimepiride group (n = 28) showed no significant differences in DFMDs (empagliflozin, −0.19 ± 2.34%; glimepiride, −0.37 ± 2.77%; P = 0.79). Likewise, glycated hemoglobin (HbA1c) changes were similar between the two groups. Body weight changes significantly differed (empagliflozin, –0.59 ± 2.5 kg; glimepiride, 1.2 ± 3.0 kg; P = 0.02). However, analysis of the body composition revealed that body fluid volume significantly decreased only after empagliflozin treatment (baseline, 35.8 ± 6.8 L; after 12 weeks, –0.33 ± 0.72 L; P = 0.03). Conclusions: Empagliflozin did not improve endothelial function compared with glimepiride in patients with type 2 diabetes, but decreased their body fluid volume. This suggested that the coronary protective effect of empagliflozin is not derived by protecting endothelial function but rather from reducing the risk of heart failure.

scholarly journals Usefulness of a Body Composition Analyzer, InBody 2.0, in Chronic Hemodialysis Patients

2006 ◽  
Vol 22 (5) ◽  
pp. 207-210 ◽  
Author(s):  
Machiko Okamoto ◽  
Mitsumine Fukui ◽  
Atsushi Kurusu ◽  
Ichiyu Shou ◽  
Kunimi Maeda ◽  
...  
Keyword(s):  
Body Composition ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Composition Analyzer

scholarly journals The Relationship Between Nephrolithiasis Risk with Body Fat Measured by Body Composition Analyzer in Obese Peopale

2017 ◽  
Vol 25 (2) ◽  
pp. 126
Author(s):  
Zohreh Bartani ◽  
Behzad Heydarpour ◽  
Ahmad Alijani ◽  
Masoud Sadeghi
Keyword(s):  
Body Composition ◽  
Body Fat ◽  
Composition Analyzer ◽  
The Relationship

Body fluid volume determination via body composition spectroscopy in health and disease

2006 ◽  
Vol 27 (9) ◽  
pp. 921-933 ◽  
Author(s):  
Ulrich M Moissl ◽  
Peter Wabel ◽  
Paul W Chamney ◽  
Ingvar Bosaeus ◽  
Nathan W Levin ◽  
...  
Keyword(s):  
Body Composition ◽  
Body Fluid ◽  
Fluid Volume ◽  
Volume Determination ◽  
Body Fluid Volume ◽  
Health And Disease
Sign in / Sign up

Export Citation Format

Share Document